Clinical trial NCT06771544: Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Official title: Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Melanoma
Melanoma Stage III
Melanoma (Skin)
Melanoma Stage IV
Keywords: Melanoma
Melanoma, Stage III
Skin
Melanoma, Stage IV
Pembrolizumab
Cyclophosphamide
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2025-01-13
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years at the time of signing informed consent form (ICF)
* Patients must have unresectable Stage III or Stage IV non-ocular melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria not amenable to local therapy
* Participants must have measurable disease by RECIST v1.1 criteria as assessed by investigator/ radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
* Participants must have Eastern Cooperative Group (ECOG) performance status score of 0, 1 or 2 at screening visit.
* Life expectancy of at least 12 weeks
* Adequate bone marrow, liver, and renal function
* Hemoglobin ≥8.0 g/dL
* Platelets ≥75/mm3
* ANC ≥1.5/mm3
* Creatinine Clearance ≥ 30mL/min Cockcroft-Gault CrCl, mL/min = (140 - age) × (weight, kg) × (0.85 if female) / (72 × Cr, mg/dL).
* AST and ALT less than 3 times the Upper Limit of Normal or less than 5 times the Upper Limit of normal with liver metastases. T Bilirubin \< 3.1 mg/dL.
* Recovered from toxicities of pembrolizumab, excluding endocrine toxicities
* Receipt of PD-1/PD-L1
* For melanoma patients: within 6 weeks (every 3 week dosing) or 9 weeks (every 6 week dosing) prior to the first dose of the investigational therapy
* Women of childbearing potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment
* Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study.
* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of study intervention; cessation of birth control after this point shall be discussed with a responsible physician.
* Pregnant or lactating women are prohibited from enrolling in this study.
* Male participants are not allowed to donate sperm from the time of enrollment until 6 months after administration of study interventions.

Exclusion Criteria:

* Participants with a diagnosis of ocular or metastatic uveal melanoma
* Participants with a history of a malignant disease other than those being treated in this study. The following exceptions are permitted:
* Malignancies that were treated curatively and have not recurred within 2 years. Shorter intervals can be considered after discussion with the Principal Investigator.
* Completely resected basal cell and squamous cell skin cancers.
* Any malignancy considered to be indolent and that has never required therapy, such as chronic lymphocytic leukemia.
* Completely resected carcinoma in situ of any type
* Participants ineligible to be retreated with pembrolizumab due to a treatment-related AE while on a prior anti-PD(L)-1 regimen that led to discontinuation of that prior therapy and would thus prevent retreatment or with an immune-related adverse event (irAE) of grade 3 or greater
* Participants with known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. NOTE: Participants with previously treated brain metastases may participate provided ALL of the following apply:
* Treated CNS lesions are radiographically stable (without evidence of progression for ≥ 28 days prior to the first dose of study intervention) after intervention (eg, surgery and/or radiation).
* Neurologically stable and on stable dose of ≤ 10mg of prednisone equivalent steroids for at least 7 days prior to the first dose of study intervention.
* Investigational or standard immunotherapy (with exception of pembrolizumab, nivolumab, or relatlimab), chemotherapy or radiation within 6-9 weeks of the first dose of the investigational therapy (see Inclusion Criteria)
* Presence of B-RAF driver mutation without prior receipt of BRAF +/- MEK inhibitors, unless patient declines BRAF +/-MEK inhibition for any reason or is unable to tolerate BRAF and/or MEK inhibitors.
* Participants with a known history of chronic viral infections as indicated below. If patients do not have a known history, testing is not required during the screening period to confirm the patient has an active infection.
* Known HBV infection defined as hepatitis B surface antigen reactive. NOTE: Participants with HBV infection on stable anti-viral therapy for \> 4 weeks prior to the planned first study intervention and viral load confirmed as undetectable during Screening may be eligible.
* Known active HCV infection defined as detectable HCV RNA (qualitative) infection. NOTE: History of HCV is not exclusionary if participant has received curative treatment and viral load is confirmed as undetectable during Screening.
* Active HIV infection. Those with HIV infections on combination antiretroviral medications with stable CD4 count \>200/microliters as measured within screening time period. If the patient does not have a known history of HIV, then testing is not required during screening to confirm presence or absence of HIV.
* Positive serum pregnancy test
* Participants with out-of-range screening laboratory values as defined below. NOTE: Hematology evaluations must be performed \>7 days from any blood transfusion. Or blood product transfusion or from any dose of hematologic growth factor.
* Glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula) \< 30 mL/min
* Total bilirubin \> 1.5 × ULN; participants with Gilbert's syndrome are excluded if total bilirubin \> 3.0 × ULN; or direct bilirubin \> 1.5 × ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): \> 2.5 × ULN (\> 5 × ULN for participants with liver metastases)
* Albumin \< 3.0 g/dL
* Absolute neutrophil count \< 1.5 × 10\^9/L
* Absolute lymphocyte count \< 0.5 × 10\^9/L
* Platelet count \< 100 × 10\^9/L
* Hemoglobin \< 9 g/dL
* Participants with a history of allogeneic tissue/solid organ transplant

Primary outcomes:
measure: Objective Response Rate (ORR) by RECIST v1.1
timeFrame: Up to 3 years
measure: Number of Patients with Adverse Events
timeFrame: Up to 3 years
measure: Number of Patients with Immune Related Adverse Events
timeFrame: Up to 3 years
measure: Number of Patients who Discontinued Treatment Due to Reported Adverse Events
timeFrame: Up to 3 years
measure: Comparative Analysis of Immune Cells
timeFrame: Up to 3 years
Secondary outcomes:
measure: Objective Response Rate (ORR) by iRECIST
timeFrame: Up to 3 years
measure: Clinical Benefit Rate
timeFrame: Up to 3 years
measure: Overall Survival
timeFrame: Up to 3 years
measure: Progression Free Survival
timeFrame: Up to 3 years.
measure: Duration of Response
timeFrame: Up to 3 years
Other outcomes:
measure: Comparison of Phenotype and T-Cell Function
timeFrame: Up to 3 years
measure: Comparative Quantitative analysis of T-Cell Repertoire
timeFrame: Up to 3 years
Locations:
city: Orange
country: United States
facility: Chao Family Comprehensive Cancer Center University of California, Irvine
state: California
Study officials:
affiliation: Chao Family Comprehensive Cancer Center
name: Warren Chow, MD
role: PRINCIPAL_INVESTIGATOR
References: